Drug Profile

EDP 494

Alternative Names: EDP-494

Latest Information Update: 31 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Enanta Pharmaceuticals
Class Antivirals
Mechanism of Action Cyclophilin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Hepatitis C

Most Recent Events

06 Jan 2017 Discontinued - Phase-I for Hepatitis C in USA
11 Nov 2016 Adverse events and pharmacokinetics data from a phase I trial in Hepatitis C (In volunteers) presented at the 67^th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)
20 Jun 2016 Enanta Pharmaceuticals completes a clinical trial in Hepatitis C (In volunteers) in USA before June 2016 (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com